Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial.
Steffen DeschUwe ZeymerIbrahim AkinMichael BehnesDaniel DuerschmiedTienush RassafAmir Abbas MahabadiRalf LehmannIngo EitelTobias GrafTim SeidlerAndreas SchusterTharusan ThevathasanCarsten SkurkPeter ClemmensenMarcus HennersdorfStephan FichtlschererIngo VoigtMelchior SeyfarthStefan JohnSebastian EwenAxel LinkeEike TiggesPeter NordbeckLeonhard BruchChristian JungJutta FranzPhilipp LautenMarko NocGeorg FuernauHans-Josef FeistritzerJanine PössEva KirchhofTaoufik OuarrakSteffen SchneiderAnne FreundHolger ThielePublished in: European heart journal (2024)
Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.
Keyphrases
- heart failure
- study protocol
- clinical trial
- phase iii
- acute myocardial infarction
- phase ii
- clinical practice
- open label
- left ventricular
- randomized controlled trial
- double blind
- type diabetes
- cardiovascular events
- cardiovascular disease
- placebo controlled
- acute coronary syndrome
- acute heart failure
- smoking cessation